{{Infobox
| title = Infliximab for Neurodegenerative Diseases
| image =
| label1 = Drug Name
| data1 = Infliximab (Remicade)
| label2 = Category
| data2 = TNF-alpha Inhibitor (Biologic)
| label3 = Target
| data3 = TNF-alpha
| label4 = Route
| data4 = Intravenous infusion
| label5 = Manufacturer
| data5 = Janssen (Johnson & Johnson)
| label6 = ClinicalTrials.gov
| data6 = NCT02878616
}}
Infliximab is a chimeric monoclonal antibody that neutralizes tumor necrosis factor-alpha (TNF-α), a pro-inflammatory cytokine central to neuroinflammation in Alzheimer's disease, Parkinson's disease, and other neurodegenerative conditions. It is FDA-approved for autoimmune diseases including rheumatoid arthritis, Crohn's disease, ulcerative colitis, and ankylosing spondylitis, and is being investigated for neuroprotection in degenerative brain diseases.
TNF-alpha is a key mediator of chronic neuroinflammation:
Pro-inflammatory Signaling: TNF-α activates NF-κB and MAPK pathways in microglia and astrocytes, leading to production of more cytokines and chemokines. This creates a self-perpetuating inflammatory loop that drives progressive neuronal dysfunction.
Excitotoxicity: TNF-α enhances glutamate-induced neuronal toxicity by increasing AMPA receptor trafficking to the synaptic membrane, leading to calcium dysregulation and excitotoxic cell death.
Blood-Brain Barrier Disruption: TNF-α increases BBB permeability by downregulating tight junction proteins (claudin-5, occludin), allowing peripheral immune cells to enter the CNS and exacerbate inflammation.
Synaptic Pruning: Elevated TNF-α promotes excessive synaptic elimination by microglia through complement-mediated pathways, contributing to synaptic loss in AD and PD.
Mitochondrial Dysfunction: TNF-α signaling impairs mitochondrial function by inhibiting complex I and increasing reactive oxygen species (ROS) production.
Infliximab is a chimeric IgG1 monoclonal antibody that:
In autoimmune diseases:
For neurodegeneration trials, similar dosing has been used:
Common (>10%):
Serious:
| Drug | Target | Route | Neurodegeneration Trials | Notes |
|---|---|---|---|---|
| Infliximab | TNF-α | IV | AD, PD (Phase II) | Chimeric antibody |
| Etanercept | TNF-α | SC | PD (mixed results) | Fusion protein |
| Adalimumab | TNF-α | SC | PD | Fully human antibody |
| Tocilizumab | IL-6R | IV/SC | AD, PD (Phase II) | Approved for RA |
| Anakinra | IL-1β | SC | AD | Short half-life |
| Secukinumab | IL-17A | SC | None | Different pathway |
The study of Infliximab For Neurodegenerative Diseases has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.